Single Plasmid Platform Increased Vaccine Yields
Researchers developed a streamlined method for producing glycoconjugate vaccines, achieving a seven-fold increase in yield.
Updated on Oct. 10, 2026 in Life Sciences
Live Poll
Do you believe new manufacturing technologies will successfully make vaccines more affordable for the public?
Scientists have developed a single constitutive plasmid platform to produce recombinant Strep A glycoconjugate vaccines. This research-stage method streamlines production by replacing traditional three-plasmid systems, which rely on complex chemical manufacturing.
Why it matters
Traditional glycoconjugate vaccine production is often expensive and complex, limiting accessibility. This simplified platform could reduce manufacturing hurdles and be applied to create vaccines against a wider range of pathogens.
The new system achieved a seven-fold higher glycoconjugate yield compared to conventional methods. It utilizes a single constitutive plasmid, removing the need for exogenous chemical inducers.
The details
Researchers used modular DNA assembly to build a single constitutive plasmid, which is a circular piece of DNA that replicates independently within a cell. This system allows for the biosynthesis of Streptococcus pyogenes rhamnose polysaccharide using Escherichia coli bacteria. By removing the requirement for exogenous chemical inducers—substances added to trigger gene expression—the process simplifies complex cell culture conditions used in traditional bioconjugation.
Timeline
- 2026-10-10
Research article published.
The Tech Race
This development optimizes existing Protein-Glycan Coupling Technology by transitioning from multi-plasmid architectures to a more efficient single-plasmid system. It follows a broader industry trend toward simplifying recombinant protein expression platforms.
This innovation is currently at the research stage and does not immediately affect vaccine availability or clinical practices. Future application of this platform could eventually lower production costs for diverse bacterial vaccines.
The takeaway
The transition to constitutive expression in vaccine manufacturing represents a significant step toward scalable, low-cost biosynthesis. Interested researchers should monitor subsequent studies for application of this platform to pathogens beyond Streptococcus pyogenes.
Further reading
For more context on vaccine production innovations, visit our Life Sciences section.
More information
Review the technical findings in the complete peer-reviewed research article.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new manufacturing technologies will successfully make vaccines more affordable for the public?
